Epigenomics AG
OJ:ECX ISIN:DE000A0BVT96
Epigenomics AG (ETR:ECX) is a Germany-based company engaged in the molecular diagnostics sector. It divides its products into two areas: solutions for early diagnosis of cancer and products for special diagnosis of cancer. Epigenomics AG produces and develops tests that help in the diagnosis of the colorectal, prostate and lung cancer. The Company also offers services in the field of identification and development of methylated deoxyribonucleic acid (DNA) biomarkers. Industry partners and the medical and life science communities can access the Company’s portfolio of filed patent families covering DNA methylation technologies and biomarkers, as well as its DNA methylation expertise through research products, biomarker services, in vitro diagnostics (IVD) development collaborations and licensing. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. The Company has a subsidiary in the United States, Epigenomics, Inc.
News
Epigenomics AG (OJ:ECX) Epigenomics AG / Contract / Ad hoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG and Abbott Molecular Inc. Expand Strategic In Vitro Diagnostics Partnership Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Epigenomics AG (OJ:ECX) Key Figures (in EUR thousand)
Epigenomics AG (OJ:ECX) - Successfully qualified 17 PRESEPT clinical sites; 12 sites initiated - Enrollment nearly 500 hundred subjects in first three months - Expanded clinical site network to include first site in Germany - Launched PRESEPT Study website found at www.presept.net - Added Prof. Dr. Thomas Rösch to the Clinical Study Steering Committee - Appointed Dr. Timothy R. Church responsible for study results analysis - Clinical Study Steering Committee recommends strengthening design by dropping interim analysis
Epigenomics AG (OJ:ECX) - Clinical study with patient cohorts from multiple clinical centers completed - All study endpoints met - PITX2 biomarker classifies patients into groups at high and low risk for relapse
Epigenomics AG (OJ:ECX) Epigenomics AG / Voting rights: Correction Release of a Voting Rights Notification (§ 21 para. 1 WpHG) released on 11 September 2008 in Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide Distribution Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Epigenomics AG (OJ:ECX) Epigenomics AG / Voting rights: Voting Rights: Release of a Voting Rights Notification (§ 21 para. 1 WpHG) in Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide Distribution Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Epigenomics AG (OJ:ECX) - Clinical study of over 500 patient samples well on track for completion in Q4 2008 - Interim analysis representing approximately half of the cases demonstrates statistical significance for primary endpoint of prostate cancer prognosis (probability of recurrence) - PITX2 biomarker classifies patients into groups at high and low risk for relapse following surgery
Epigenomics AG / Voting Rights: Release of a Voting Rights Notification (§ 21 para. 1 WpHG) in Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide Distribution Publication pursuant to §26 sect.1 WpHG processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
###
1,691 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 3) (Last 30 Days: 20) (Since Published: 1691)
